Cost-effectiveness of herpes zoster vaccine: Flawed assumptions regarding efficacy against postherpetic neuralgia

Clinical Infectious Diseases

Volumn 45, Issue 11, 2007, Pages 1527-1529

  Brisson, Marc ^a,b   Pellissier, James M ^c   Levin, Myron J ^d  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; LETTER; MORBIDITY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; VACCINATION; AGED; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGY; NOTE;

AGED; COST-BENEFIT ANALYSIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; NEURALGIA, POSTHERPETIC;

EID: 85047682130     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522769     Document Type: Letter

References (3)

1. Rothberg MB, Virapongse A, Smith K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280-8.
2. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the U.S. of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine (in press).
3. Oxman MN, Levin MJ, Johnson GR, Schmader K; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.